Ekso Bionics Holdings, INC Form 4 insider transactions

Rajasekar Jegannathan, Chief Technology Officer of Ekso Bionics Holdings, Inc., received 1,400,000 shares of common stock on July 22, 2026.

Ying Cenly Chen, Chief Executive Officer and a Director of Ekso Bionics Holdings, Inc., received 2,800,000 shares of common stock on July 13, 2026.

ChronoScale Corp director Andrew Schaap acquired 200,000 restricted shares of common stock on June 29, 2026, as part of a grant with a two-year vesting schedule.

Director William M. Clancy was granted 200,000 restricted shares of ChronoScale Corp common stock on May 14, 2026.

Director Wes Cummins was granted 200,000 restricted shares of ChronoScale Corp common stock, vesting over a two-year period.

Director Ella G. Benson was granted 200,000 restricted shares of ChronoScale Corp common stock on May 14, 2026.

Director Richard Nottenburg was granted 200,000 restricted shares of ChronoScale Corp common stock vesting over two years.

ChronoScale Corp CFO Jerome Wong acquired 40,000 shares of common stock following the vesting of performance-based restricted stock units.

Director Douglas S. Miller was granted 200,000 restricted shares of ChronoScale Corp common stock, vesting over two years.

Director Scott G. Davis acquired 109,357 shares of ChronoScale Corp common stock following the vesting of performance-based restricted stock units.

EKSO Bionics Holdings' Chief Operating Officer, Jason C. Jones, acquired 1,308 common shares at $11.85 each through the company's 401(k) matching program.

Jerome Wong, Chief Financial Officer of EKSO Bionics Holdings, Inc., acquired 1,308 shares of common stock at $11.85 per share through the company's 401(k) matching program.

Daniel Asher, a Director and 10% owner of EKSO Bionics, has filed a Form 4 detailing planned future acquisitions and dispositions of company stock under a Rule 10b5-1 plan.

EKSO Bionics Director Daniel Asher acquired 1,200 shares of common stock at $9.60 per share through an indirect holding.

EKSO Bionics Holdings' Chief Operating Officer, Jason C. Jones, sold 1,320 shares of common stock at $9.25 per share to cover tax withholding obligations.

EKSO Bionics Holdings' Chief Operating Officer, Jason C. Jones, sold 270 shares of common stock to cover tax withholding obligations.

EKSO Bionics CFO Jerome Wong sold 1,238 shares of common stock to cover tax withholding obligations related to vested restricted stock awards.

EKSO Bionics CFO Jerome Wong sold 11,288 shares of common stock at $4.7990 per share to cover tax withholding obligations related to restricted stock awards.

EKSO Bionics Holdings' Chief Operating Officer, Jason C. Jones, sold 9,723 shares of common stock on November 10, 2025, to cover tax withholding obligations.

EKSO Bionics CEO Scott G. Davis sold 23,315 shares of common stock on November 10, 2025, to cover tax withholding obligations related to restricted stock awards.

EKSO Bionics Holdings, Inc. CEO Scott G. Davis was granted 80,000 fully vested restricted stock units, adjusted for a recent 1-for-15 reverse stock split.

EKSO Bionics Holdings' Chief Operating Officer, Jason C. Jones, was granted 15,000 fully vested restricted stock units on November 5, 2025.

EKSO Bionics Holdings, Inc. Chief Financial Officer Jerome Wong received a grant of 19,500 fully vested restricted stock units on November 5, 2025, increasing his direct beneficial ownership.

Director Mary Ann Cloyd reports acquiring and disposing of Ekso Bionics Holdings, Inc. shares, including restricted stock units (RSUs), following the company's annual meeting.

Director Corinna Lathan reports acquisition of 236,202 restricted stock units (RSUs) in Ekso Bionics Holdings, Inc. following the company's annual meeting.

Director Li Kecheng reports acquisition of 236,202 restricted stock units (RSUs) in Ekso Bionics Holdings, Inc.

Director Deborah Lafer Scher acquired 236,202 restricted stock units in Ekso Bionics Holdings, Inc., increasing her total holdings to 314,419 shares.

Chief Financial Officer Jerome Wong reports acquiring 24,248 shares of Ekso Bionics Holdings, Inc. common stock through the company's 401(k) contribution matching program.

Jason C. Jones, Chief Operating Officer of Ekso Bionics Holdings, Inc., acquired 24,248 shares of common stock through the company's 401(k) contribution matching program.

CEO Scott G. Davis acquired 5,590 shares of Ekso Bionics through the company's 401(k) contribution matching program.